Full metadata record
DC FieldValueLanguage
dc.creatorCalasanz-Abinzano, M.J. (Maria Jose)-
dc.creatorCigudosa, J.C. (Juan Cruz)-
dc.creatorOdero, M.D. (Maria Dolores)-
dc.creatorFerreira, C. (C.)-
dc.creatorArdanaz, M.T. (M.T.)-
dc.creatorFraile, A. (A.)-
dc.creatorCarrasco, J. (J.L.)-
dc.creatorSole, F. (Francesc)-
dc.creatorCuesta, B. (Braulia)-
dc.creatorGullon, A. (Arturo)-
dc.date.accessioned2011-11-15T10:01:18Z-
dc.date.available2011-11-15T10:01:18Z-
dc.date.issued1997-
dc.identifier.citationCalasanz MJ, Cigudosa JC, Odero MD, Ferreira C, Ardanaz MT, Fraile A, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer 1997 Feb;18(2):84-93.es_ES
dc.identifier.issn1098-2264-
dc.identifier.urihttp://hdl.handle.net/10171/19794-
dc.description.abstractCytogenetic analysis of unstimulated short-term bone marrow cell cultures was performed on 280 patients with multiple myeloma and related disorders. In 65% of the cases, an additional short term B-cell stimulated culture was also examined. Chromosomally abnormal clones were found in 31% of the patients, 15% in Waldenström macroglobulinemia. 25% in monoclonal gammopathies, 33% in multiple myeloma, and 50% in plasma cell leukemia. Three primary chromosomal breakpoints were recurrently involved: 14q32, 16q22, and 22q11. Structural rearrangements of chromosome 1 were the most frequent (26% of the abnormal cases), but always as a secondary change. Rearrangements of band 14q32 were found in 22% of the abnormal cases. Among the multiple myeloma patients who showed an abnormal karyotype, 33 (46%) were hyperdiploid, most frequently, with 52-56 chromosomes, 29 patients (40%) were pseudodiploid, and the remaining 12 cases (14%) were hypodiploid. A highly significant relation was observed between the presence of an abnormal karyotype and the following clinical parameters: stage III (P = 0.0001), bone marrow plasma cell infiltration greater than 30% (P = 0.0001), presence of bone lesions (P = 0.0009), and beta 2-microglobulin levels greater than 4 mg/L (P = 0.0001).es_ES
dc.language.isoenges_ES
dc.publisherWiley-Blackwelles_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectChromosome Aberrationses_ES
dc.subjectChromosome Disorderses_ES
dc.subjectMultiple Myeloma/geneticses_ES
dc.titleCytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlationses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://bit.ly/tq2BMaes_ES

Files in This Item:
File: 
1997 GChromC Calasanz.pdf
Description: 
Size: 
121,59 kB
Format: 
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.